Company intelligence
iVigee
About iVigee
iVigee delivers physician-led pharmacovigilance grounded in truth. You receive pharmacovigilance services and consulting across the entire product lifecycle, from clinical development through post-marketing authorization. Our approach is built on transparency, regulatory realism, and straight answers you can trust, so you’re never left guessing. You work with physicians, former regulators, EU QPPVs, and senior safety leaders who understand how pharmacovigilance is evaluated in real inspections. We focus on what regulators actually look for, what they question, and what they expect you to explain, not just what guidance says. We support you as you build, optimize, and transform your pharmacovigilance capabilities, providing clarity at every stage, from early system design through mature, inspection-ready operations. Across everything we do, you always know where you stand, before inspections, before submissions, and before issues become findings. iVigee operates under an ISO 9001: 2015 – certified quality management system, ensuring the way we work is as structured, consistent, and accountable as the systems we help you establish and maintain.
Verified activity
Signals from iVigee
13 published signals
Presence & Recognition
iVigee hosted a conversation between Henry Seto and Jan Petracek discussing how AI is changing pharmacovigilance work and supervising it.
Reported by Lewis Atkinson (M.APS)
Presence & Recognition
iVigee hosted a conversation with Henry Seto discussing AI taking over daily pharmacovigilance work and supervising it.
Reported by Jan Petracek
Research & Knowledge
iVigee published the Netherlands policy on risk minimization measures
Reported by Lewis Atkinson (M.APS)
Research & Knowledge
iVigee published the Chinese translation of ICH E2D(R1) for consultation in China
Reported by Lewis Atkinson (M.APS)
Research & Knowledge
iVigee published a question regarding CRO or specialist pharmacovigilance provider for growing biotechs
Reported by Lewis Atkinson (M.APS)
Legal & Regulatory
iVigee published the Netherlands policy on risk minimization measures
Reported by Marcela Fialova
Legal & Regulatory
iVigee published the Chinese translation of ICH E2D(R1) for consultation in China
Reported by Marcela Fialova
Legal & Regulatory
iVigee reports that the Netherlands has updated its policy on risk minimization measures.
Reported by Natalia Kalousova Kocankova
Legal & Regulatory
iVigee reports that China's Chinese translation of ICH E2D(R1) is out for consultation.
Reported by Natalia Kalousova Kocankova
Research & Knowledge
iVigee published a Signal Watch article covering China's Chinese translation of ICH E2D(R1) for consultation and the Netherlands' updated policy on risk minimization measures.
Reported by Jan Petracek
Research & Knowledge
iVigee published the Expert Series asking CRO vs. Specialist Pharmacovigilance Provider: Which Should You Actually Choose?
Reported by iVigee
Legal & Regulatory
iVigee reports that the Medicines Evaluation Board in the Netherlands has updated its policy on additional risk minimisation measures.
Reported by iVigee
Legal & Regulatory
iVigee reports that the Center for Drug Evaluation in China has opened a public consultation regarding the Chinese translation of the ICH E2D(R1) information paper.
Reported by iVigee